Atish D. Choudhury, MD, PhD

Dr Choudhury on the Evaluation of Treatment Interruption After Response in mHSPC

June 17th 2024

Atish D. Choudhury, MD, PhD, on a phase 2 trial evaluating ADT interruption in metastatic hormone-sensitive prostate cancer after AR inhibitor response.

Dr. Choudhury on The Need for Biomarkers to Predict Benefit With PARP Inhibitors in mCRPC

February 14th 2023

Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.

Dr. Choudhury on the Potential Benefit of PARP Inhibitor Use in mCRPC

February 8th 2023

Atish D. Choudhury, MD, PhD, discusses key biomarkers that may assist in the prediction of PARP inhibitor benefit in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Choudhury on Emerging Treatment Strategies in mCRPC

June 15th 2021

Atish D. Choudhury, MD, PhD, discusses emerging treatment strategies in metastatic castration-resistant prostate cancer.

Dr. Choudhury on Future Research Directions for Pembrolizumab/Radium-223 in mCRPC

April 26th 2021

Atish D. Choudhury, MD, PhD, discusses future research directions for the combination of pembrolizumab and radium-223 dichloride in patients with metastatic castration-resistant prostate cancer.

Dr. Choudhury on the Rationale Behind Adding Pembrolizumab to Radium-223 in mCRPC

February 11th 2021

Atish D. Choudhury, MD, PhD, discusses the rationale behind combining pembrolizumab with radium-223 in patients with metastatic castration-resistant prostate cancer as part of a phase 2 clinical trial.

Dr. Choudhury on the Designs of Key Trials in Nonmetastatic CRPC

September 29th 2020

Atish D. Choudhury, MD, PhD, discusses the design of key clinical trials in nonmetastatic castration-resistant prostate cancer.

Dr. Choudhury on Treatment Goals in Nonmetastatic CRPC

September 23rd 2020

Atish D. Choudhury, MD, PhD, discusses the goal of treating patients with nonmetastatic castration-resistant prostate cancer.

Dr. Choudhury on the Safety Profiles of Antiandrogens in Nonmetastatic CRPC

September 22nd 2020

Atish D. Choudhury, MD, PhD, compares the safety profiles of antiandrogen agents in nonmetastatic castration-resistant prostate cancer.

Dr. Choudhury on the Different States of Nonmetastatic CRPC

September 21st 2020

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Dr. Choudhury on Clinical Trials of Interest in Nonmetastatic CRPC

September 14th 2020

Atish D. Choudhury, MD, PhD, discusses clinical trials of interest examining different agents, such as darolutamide, enzalutamide, and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Dr. Choudhury on Antiandrogen Treatment Selection in Nonmetastatic CRPC

September 9th 2020

Atish D. Choudhury, MD, PhD, discusses antiandrogen treatment selection in nonmetastatic castration-resistant prostate cancer.

Dr. Choudhury on the Use of Radiopharmaceuticals in Prostate Cancer

July 24th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of radiopharmaceuticals in the treatment of patients with prostate cancer.

Dr. Choudhury on Targeted Therapy in Prostate Cancer

June 28th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the use of targeted therapy in prostate cancer.

Dr. Choudhury on the Importance of Volume Status in Metastatic Prostate Cancer

June 12th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses the importance of volume status in prostate cancer.

Dr. Choudhury on Immunotherapy in Metastatic CRPC

May 10th 2019

Atish D. Choudhury, MD, PhD, co-director of the Prostate Cancer Center, senior physician, Dana-Farber Cancer Institute, and instructor in medicine, Harvard Medical School, discusses data with immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).